Mainz Biomed NV (NASDAQ:MYNZ) has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert,

Mainz Biomed NV (NASDAQ:MYNZ) has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert, a detection test for colorectal cancer (CRC). 

美因茨比亚德NV纳斯达克(Sequoia Capital：MYNZ)与法国兴业银行(Socpra Sciences Santéet Humaines)签署了一项技术权利协议，将访问一系列生物标志物，用于未来整合到结直肠癌检测测试ColoAlert中。